Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsLSE:CRTX -5.00% Gross Margin % is 58.01% as of Dec. 2025, which is 2% above its 10-year median of 56.71. The stock has 3 warning signs investors should review. Among 733 Biotechnology companies, Crism Therapeutics ranks worse than 54.57% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Crism Therapeutics had a gross margin of 58.01% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Crism Therapeutics Gross Margin % Related Terms
Crism Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CRTX vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Crism Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Crism Therapeutics (LSE:CRTX) has a Gross Margin % of 58.01% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Crism Therapeutics and its competitors. This is near median its historical median of 56.71. Over the past decade, Crism Therapeutics' Gross Margin % has ranged from 28.89 to 84.00. According to the industry distribution chart, Crism Therapeutics ranks #400 out of 733 companies in the Biotechnology industry, placing it in the top 54.6%.
Is Crism Therapeutics' Gross Margin % too high?
Crism Therapeutics' current Gross Margin % of 58.01% is near median its 10-year median of 56.71. Over the past 10 years, this metric has ranged from a low of 28.89 to a high of 84.00. The Biotechnology industry median Gross Margin % is 60.91. Crism Therapeutics' value of 58.01% is 4.8% below this industry median. Based on the distribution chart, Crism Therapeutics ranks #400 out of 733 companies in the Biotechnology industry, which is below the industry midpoint.
How does Crism Therapeutics' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #400 out of 733 companies for Gross Margin %. This places Crism Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.91. Crism Therapeutics' value of 58.01% is 4.8% below this benchmark. Historically, Crism Therapeutics' own Gross Margin % has ranged from 28.89 to 84.00 over the past decade. While the company's 10-year median is 56.71 vs. the industry median of 60.91, Crism Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crism Therapeutics's current Gross Margin % of 58.01% is 4.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Crism Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current Gross Margin % is 58.01%, which is near median its own 10-year median of 56.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (LSE:CRTX) has a current Gross Margin % of 58.01%. The current Gross Margin % is 58.01%, which is near median its 10-year median of 56.71 and 4.8% below the Biotechnology industry median of 60.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Crism Therapeutics (LSE:CRTX), the current Gross Margin % is 58.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CRTX has been successfully added to your 
